Physician profile
Alfredo E Torres
NPI 1033178975
$14,776.35
in general payments reported to CMS, 2019-2025
30 companies · $3,978 in 2025
The $3,978 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,647 · 2020: $1,156 · 2021: $2,065 · 2022: $2,240 · 2023: $2,233 · 2024: $1,457 · 2025: $3,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,970 · Consulting Fee: $1,650 · Education: $48.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,970.32 |
| Consulting Fee | $1,650.00 |
| Education | $48.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,799.87 | 2019-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $2,232.27 | 2019-2025 | Nuplazid |
| Beone Medicines USA, INC. | $1,650.00 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $1,320.98 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $990.74 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $748.12 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $710.47 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $532.53 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $491.01 | 2019-2022 | |
| Abbvie INC. | $488.63 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $391.35 | 2019-2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $339.16 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $325.10 | 2023-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $281.43 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $273.75 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $254.58 | 2024-2025 | Cobenfy |
| Eisai INC. | $211.61 | 2020-2023 | |
| Allergan, INC. | $203.38 | 2019-2020 | |
| Livanova USA, INC. | $134.57 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator, Vns Therapy Sentiva Model 1000 Generator |
| Idorsia Pharmaceuticals US INC | $102.04 | 2022-2023 | Quviviq |
| Indivior INC. | $100.99 | 2022-2023 | Perseris |
| Merck Sharp & Dohme LLC | $58.77 | 2020-2022 | |
| Alpha Cognition USA, INC. | $38.71 | 2025 | Zunveyl |
| Shire North American Group INC | $31.01 | 2019 | |
| Almatica Pharma LLC | $24.49 | 2022 | |
| Bioxcel Therapeutics, INC. | $15.23 | 2024 | Igalmi |
| Supernus Pharmaceuticals, INC. | $14.73 | 2022 | |
| Sanofi Pasteur INC. | $10.83 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.